Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASPIAN-RT: Hypofractionated RT after Durvalumab + Chemo in ES-SCLC
NCT05161533Phase 2Withdrawn
- Sponsor
- University of Washington
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by University of Washington. Primary endpoint: Progression free survival at 3 years. Planned start Oct 2023; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05161533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161533.